OBJECTIVES: Identification of HIV infection in exposed infants facilitates early therapy, which may limit viral reservoirs that maintain HIV infection under HAART. METHODS: The dynamics of the resting CD4 T-cell latent HIV reservoir was determined over the first 2 years of life in 17 HIV-infected infants initiating lopinavir/ritonavir-based HAART at a median age of 8.1 weeks and achieving adequate suppression of plasma viral load by 24 weeks. RESULTS: The resting CD4 T-cell latent HIV reservoir was detected in 12 of 14 (86%) infants tested at 24 weeks of HAART [median frequency 1.88 infectious units per million (IUPM); range <0.22 to 81.7), and remained measurable (median IUPM = 0.32; range <0.22 to 3.25) in six of 10 (60%) children retested at 96 weeks. The reservoir declined, from 24 to 96 weeks of HAART, at an estimated mean rate of 0.028 log10 IUPM/month, corresponding to a half-life of 11 months (95% confidence interval 6-30 months]. A strong relationship was found between the frequency of latently infected CD4 T cells at 96 weeks of HAART and time to first undetectable plasma viral load (Spearman r = 0.91, P < 0.001). CONCLUSION: Although the resting CD4 T-cell latent reservoir remains detectable over the first 2 years of HAART in a substantial proportion of infants, its size is associated with time to first undetectable viral load. To minimize HIV reservoirs in infants, rapid curtailment of viremia may limit HIV reservoirs and should be a therapeutic goal of early HAART in infants.
OBJECTIVES: Identification of HIV infection in exposed infants facilitates early therapy, which may limit viral reservoirs that maintain HIV infection under HAART. METHODS: The dynamics of the resting CD4 T-cell latent HIV reservoir was determined over the first 2 years of life in 17 HIV-infectedinfants initiating lopinavir/ritonavir-based HAART at a median age of 8.1 weeks and achieving adequate suppression of plasma viral load by 24 weeks. RESULTS: The resting CD4 T-cell latent HIV reservoir was detected in 12 of 14 (86%) infants tested at 24 weeks of HAART [median frequency 1.88 infectious units per million (IUPM); range <0.22 to 81.7), and remained measurable (median IUPM = 0.32; range <0.22 to 3.25) in six of 10 (60%) children retested at 96 weeks. The reservoir declined, from 24 to 96 weeks of HAART, at an estimated mean rate of 0.028 log10 IUPM/month, corresponding to a half-life of 11 months (95% confidence interval 6-30 months]. A strong relationship was found between the frequency of latently infected CD4 T cells at 96 weeks of HAART and time to first undetectable plasma viral load (Spearman r = 0.91, P < 0.001). CONCLUSION: Although the resting CD4 T-cell latent reservoir remains detectable over the first 2 years of HAART in a substantial proportion of infants, its size is associated with time to first undetectable viral load. To minimize HIV reservoirs in infants, rapid curtailment of viremia may limit HIV reservoirs and should be a therapeutic goal of early HAART in infants.
Authors: W S Hlavacek; N I Stilianakis; D W Notermans; S A Danner; A S Perelson Journal: Proc Natl Acad Sci U S A Date: 2000-09-26 Impact factor: 11.205
Authors: Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano Journal: Nat Med Date: 2003-05-18 Impact factor: 53.440
Authors: B Ramratnam; J E Mittler; L Zhang; D Boden; A Hurley; F Fang; C A Macken; A S Perelson; M Markowitz; D D Ho Journal: Nat Med Date: 2000-01 Impact factor: 53.440
Authors: Daniel C Douek; Jason M Brenchley; Michael R Betts; David R Ambrozak; Brenna J Hill; Yukari Okamoto; Joseph P Casazza; Janaki Kuruppu; Kevin Kunstman; Steven Wolinsky; Zvi Grossman; Mark Dybul; Annette Oxenius; David A Price; Mark Connors; Richard A Koup Journal: Nature Date: 2002-05-02 Impact factor: 49.962
Authors: J N Blankson; D Finzi; T C Pierson; B P Sabundayo; K Chadwick; J B Margolick; T C Quinn; R F Siliciano Journal: J Infect Dis Date: 2000-11-08 Impact factor: 5.226
Authors: Christian T Ruff; Stuart C Ray; Patricia Kwon; Rebekah Zinn; Amanda Pendleton; Nancy Hutton; Roxann Ashworth; Stephen Gange; Thomas C Quinn; Robert F Siliciano; Deborah Persaud Journal: J Virol Date: 2002-09 Impact factor: 5.103
Authors: William T Shearer; Howard M Rosenblatt; Rebecca S Gelman; Rebecca Oyomopito; Susan Plaeger; E Richard Stiehm; Diane W Wara; Steven D Douglas; Katherine Luzuriaga; Elizabeth J McFarland; Ram Yogev; Mobeen H Rathore; Wende Levy; Bobbie L Graham; Stephen A Spector Journal: J Allergy Clin Immunol Date: 2003-11 Impact factor: 10.793
Authors: Katherine Luzuriaga; Barbara Tabak; Manuel Garber; Ya Hui Chen; Carrie Ziemniak; Margaret M McManus; Danielle Murray; Matthew C Strain; Douglas D Richman; Tae-Wook Chun; Coleen K Cunningham; Deborah Persaud Journal: J Infect Dis Date: 2014-05-21 Impact factor: 5.226
Authors: Alfredo Tagarro; Man Chan; Paola Zangari; Bridget Ferns; Caroline Foster; Anita De Rossi; Eleni Nastouli; María A Muñoz-Fernández; Diana Gibb; Paolo Rossi; Carlo Giaquinto; Abdel Babiker; Claudia Fortuny; Riccardo Freguja; Nicola Cotugno; Ali Judd; Antoni Noguera-Julian; María Luisa Navarro; María José Mellado; Nigel Klein; Paolo Palma; Pablo Rojo Journal: J Acquir Immune Defic Syndr Date: 2018-10-01 Impact factor: 3.731
Authors: A Bamford; A Turkova; H Lyall; C Foster; N Klein; D Bastiaans; D Burger; S Bernadi; K Butler; E Chiappini; P Clayden; M Della Negra; V Giacomet; C Giaquinto; D Gibb; L Galli; M Hainaut; M Koros; L Marques; E Nastouli; T Niehues; A Noguera-Julian; P Rojo; C Rudin; H J Scherpbier; G Tudor-Williams; S B Welch Journal: HIV Med Date: 2015-02-03 Impact factor: 3.180
Authors: Caroline C King; Athena P Kourtis; Deborah Persaud; Julie A E Nelson; Carrie Ziemniak; Michael G Hudgens; Gerald Tegha; Charles S Chasela; Denise J Jamieson; Charles M van der Horst Journal: AIDS Date: 2015-09-24 Impact factor: 4.177
Authors: Mary Grace Katusiime; Elias K Halvas; Imogen Wright; Kevin Joseph; Michael J Bale; Bronwyn Kirby-McCullough; Susan Engelbrecht; Wei Shao; Wei-Shau Hu; Mark F Cotton; John W Mellors; Mary F Kearney; Gert U van Zyl Journal: J Virol Date: 2020-01-31 Impact factor: 5.103